Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1026695 | 0.98 | TAAR1 (0.59) | TAAR1ATMALDH1A1HTTKDM4E | |
| SCHEMBL21243271 | 0.84 | CHRM2 (0.59) | TAAR1HTTHTR1ACHRM2MEN1 | |
| SCHEMBL13369612 | 0.83 | TAAR1 (0.52) | TAAR1ATMALDH1A1HTTKDM4E | |
| SCHEMBL18731645 | 0.83 | TAAR1 (0.52) | TAAR1ALDH1A1HTTCHRM2MEN1 | |
| SCHEMBL6114374 | 0.80 | TAAR1 (0.54) | TAAR1ALDH1A1HTTKDM4ECHRM2 | |
| SCHEMBL21389316 | 0.80 | TAAR1 (0.59) | TAAR1ALDH1A1HTTKDM4EHTR1A | |
| SCHEMBL17919372 | 0.80 | TAAR1 (0.54) | TAAR1ALDH1A1HTTCHRM2MEN1 | |
| SCHEMBL143962 | 0.80 | TAAR1 (0.71) | TAAR1ALDH1A1CHRM2LMNAKMT2A | |
| SCHEMBL10725177 | 0.78 | TAAR1 (0.52) | TAAR1HTTHTR2ACHRM2MEN1 | |
| Hydrochloric Acid SCHEMBL11568175 | 0.78 | TAAR1 (0.57) | TAAR1ALDH1A1HTTKDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3433247-B1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3390400-B1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3484481-B1 | METHODS FOR USE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE | SCRIPPS RESEARCH INST (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | Bristl-Myers Squibb Company (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3362442-B1 | 2,4-DIHYDROXY-NICOTINAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3530660-A1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Bristol-Myers Squibb Company (US) | 2019-08-28 | — | — | EP | disclosed |
| US-10336739-B2 | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3303330-B1 | 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| WO-2011043480-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | 田辺三菱製薬株式会社 (JP) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043479-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | 田辺三菱製薬株式会社 (JP) | 2011-04-14 | — | — | WO | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
| WO-2009125853-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | 田辺三菱製薬株式会社 (JP) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336739-B2 | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists | TBXA2R, ADRA2C, ADRA2A | TAAR1 507/4885ATM 3668/4885ALDH1A1 914/4885 |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | APLNR, GPBAR1, AGTR1 | TAAR1 295/4885ATM 2754/4885ALDH1A1 912/4885 |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | TAAR1 3031/4885ATM 3945/4885ALDH1A1 180/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | TAAR1 2120/4885ATM 3042/4885ALDH1A1 600/4885 |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | TAAR1 4519/4885ATM 3588/4885ALDH1A1 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.